Today
-1.42%
5 Days
+2.30%
1 Month
+17.34%
6 Months
+50.53%
Year to Date
+18.79%
1 Year
+45.46%
• Amgen exceeded second-quarter earnings estimates and raised its full-year guidance. • Positive clinical data for obesity drug MariTide drove share price appreciation. • Technical indicators including MACD and Williams %R suggest a current buy signal.
• IQVIA beat Q1 2026 earnings and revenue expectations. • Company raised full-year adjusted EPS guidance and reaffirmed revenue. • Both segments showed strength, with AI driving commercial solutions growth.


| Shareholders | Proportion |
|---|---|
| Harris Associates L.P. | 6.78% |
| Vanguard Capital Management, LLC | 6.61% |
| BlackRock Institutional Trust Company, N.A. | 5.19% |
| Vanguard Portfolio Management, LLC | 4.54% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 48.99% |
| Investment Advisor/Hedge Fund | 38.83% |
| Sovereign Wealth Fund | 5.32% |
| Hedge Fund | 2.94% |
Related Instruments
Popular Instruments